IBDEI0Y9 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15259,1,4,0)
 ;;=4^Z59.0
 ;;^UTILITY(U,$J,358.3,15259,2)
 ;;=^5063129
 ;;^UTILITY(U,$J,358.3,15260,0)
 ;;=D68.59^^85^844^37
 ;;^UTILITY(U,$J,358.3,15260,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15260,1,3,0)
 ;;=3^Hypercoagulable state,Primary
 ;;^UTILITY(U,$J,358.3,15260,1,4,0)
 ;;=4^D68.59
 ;;^UTILITY(U,$J,358.3,15260,2)
 ;;=^5002360
 ;;^UTILITY(U,$J,358.3,15261,0)
 ;;=E78.2^^85^844^39
 ;;^UTILITY(U,$J,358.3,15261,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15261,1,3,0)
 ;;=3^Hyperlipidemia,LDL & Triglycerides
 ;;^UTILITY(U,$J,358.3,15261,1,4,0)
 ;;=4^E78.2
 ;;^UTILITY(U,$J,358.3,15261,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,15262,0)
 ;;=E78.00^^85^844^40
 ;;^UTILITY(U,$J,358.3,15262,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15262,1,3,0)
 ;;=3^Hyperlipidemia,LDL only
 ;;^UTILITY(U,$J,358.3,15262,1,4,0)
 ;;=4^E78.00
 ;;^UTILITY(U,$J,358.3,15262,2)
 ;;=^5138435
 ;;^UTILITY(U,$J,358.3,15263,0)
 ;;=E78.1^^85^844^41
 ;;^UTILITY(U,$J,358.3,15263,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15263,1,3,0)
 ;;=3^Hyperlipidemia,Triglycerides only
 ;;^UTILITY(U,$J,358.3,15263,1,4,0)
 ;;=4^E78.1
 ;;^UTILITY(U,$J,358.3,15263,2)
 ;;=^101303
 ;;^UTILITY(U,$J,358.3,15264,0)
 ;;=I10.^^85^844^43
 ;;^UTILITY(U,$J,358.3,15264,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15264,1,3,0)
 ;;=3^Hypertension (Essential)
 ;;^UTILITY(U,$J,358.3,15264,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,15264,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,15265,0)
 ;;=R09.02^^85^844^46
 ;;^UTILITY(U,$J,358.3,15265,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15265,1,3,0)
 ;;=3^Hypoxemia
 ;;^UTILITY(U,$J,358.3,15265,1,4,0)
 ;;=4^R09.02
 ;;^UTILITY(U,$J,358.3,15265,2)
 ;;=^332831
 ;;^UTILITY(U,$J,358.3,15266,0)
 ;;=Z59.6^^85^844^47
 ;;^UTILITY(U,$J,358.3,15266,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15266,1,3,0)
 ;;=3^Low income
 ;;^UTILITY(U,$J,358.3,15266,1,4,0)
 ;;=4^Z59.6
 ;;^UTILITY(U,$J,358.3,15266,2)
 ;;=^5063135
 ;;^UTILITY(U,$J,358.3,15267,0)
 ;;=E88.81^^85^844^48
 ;;^UTILITY(U,$J,358.3,15267,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15267,1,3,0)
 ;;=3^Metabolic syndrome
 ;;^UTILITY(U,$J,358.3,15267,1,4,0)
 ;;=4^E88.81
 ;;^UTILITY(U,$J,358.3,15267,2)
 ;;=^5003032
 ;;^UTILITY(U,$J,358.3,15268,0)
 ;;=E66.01^^85^844^49
 ;;^UTILITY(U,$J,358.3,15268,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15268,1,3,0)
 ;;=3^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,15268,1,4,0)
 ;;=4^E66.01
 ;;^UTILITY(U,$J,358.3,15268,2)
 ;;=^5002826
 ;;^UTILITY(U,$J,358.3,15269,0)
 ;;=E66.2^^85^844^50
 ;;^UTILITY(U,$J,358.3,15269,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15269,1,3,0)
 ;;=3^Morbid Obesity w/ Alveolar hypoventilation
 ;;^UTILITY(U,$J,358.3,15269,1,4,0)
 ;;=4^E66.2
 ;;^UTILITY(U,$J,358.3,15269,2)
 ;;=^5002829
 ;;^UTILITY(U,$J,358.3,15270,0)
 ;;=I25.2^^85^844^51
 ;;^UTILITY(U,$J,358.3,15270,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15270,1,3,0)
 ;;=3^Myocardial infarction,Hx of
 ;;^UTILITY(U,$J,358.3,15270,1,4,0)
 ;;=4^I25.2
 ;;^UTILITY(U,$J,358.3,15270,2)
 ;;=^259884
 ;;^UTILITY(U,$J,358.3,15271,0)
 ;;=I21.4^^85^844^52
 ;;^UTILITY(U,$J,358.3,15271,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15271,1,3,0)
 ;;=3^Myocardial infarction,NSTEMI
 ;;^UTILITY(U,$J,358.3,15271,1,4,0)
 ;;=4^I21.4
 ;;^UTILITY(U,$J,358.3,15271,2)
 ;;=^5007088
 ;;^UTILITY(U,$J,358.3,15272,0)
 ;;=I21.3^^85^844^53
 ;;^UTILITY(U,$J,358.3,15272,1,0)
 ;;=^358.31IA^4^2
